DW1029M, a novel botanical drug candidate, inhibits advanced glycation end-product formation, rat lens aldose reductase activity, and TGF-[Beta]1 signaling

DW1029M is a botanical extract consisting of Morus bark and Puerariae radix, produced by Dong-Wha Pharmaceutical, for nephroprotective drug development; it has been in phase II clinical trials in Korea. In our mechanistic investigations, we found that DW1029M inhibits advanced glycation end products...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Renal physiology Vol. 306; no. 10; p. F1161
Main Authors Yoon, Joobyoung, Lee, Hyunyong, Chang, Hwan Bong, Choi, Hyunsik, Kim, Yong Sung, Rho, Yang Kook, Seong, Seungkyoo, Choi, Dong Hwa, Park, Dongeun, Ku, Bonchul
Format Journal Article
LanguageEnglish
Published Bethesda American Physiological Society 15.05.2014
Subjects
Cells
Clinical trials
Diabetic retinopathy
Pharmaceuticals
R&D
Research & development
Rodents
Signal transduction
South Korea
Online AccessGet full text

Cover

More Information
Summary:DW1029M is a botanical extract consisting of Morus bark and Puerariae radix, produced by Dong-Wha Pharmaceutical, for nephroprotective drug development; it has been in phase II clinical trials in Korea. In our mechanistic investigations, we found that DW1029M inhibits advanced glycation end products (AGEs), rat lens aldose reductase (RLAR), and transforming growth factor (TGF)-β1 signaling, all of which are implicated in diabetic complications such as diabetic nephropathy and diabetic retinopathy. DW1029M inhibits AGE formation via ... chelation. The extract contains 13 active constituents that inhibit AGE formation, 8 active constituents that inhibit RLAR activity, and 1 inhibitor of TGF-β1 signaling. Our results suggest DW1029M protects against diabetic nephropathy via blockade of AGE formation, RLAR activity, and TGF-β1 signaling. (ProQuest: ... denotes formulae/symbols omitted.)
ISSN:1931-857X
1522-1466